MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

44.37 -1.38

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

43.78

Massimo

45.02

Metriche Chiave

By Trading Economics

Entrata

-19M

-116M

Vendite

670K

1M

Margine di Profitto

-11,216.004

Dipendenti

437

EBITDA

-19M

-129M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+79.39% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.3B

3.9B

Apertura precedente

45.75

Chiusura precedente

44.37

Notizie sul Sentiment di mercato

By Acuity

50%

50%

158 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 ott 2025, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Caterpillar to Acquire Australia's RPM Global for $730 Million

10 ott 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12 ott 2025, 23:47 UTC

Discorsi di Mercato

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12 ott 2025, 23:39 UTC

Discorsi di Mercato

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12 ott 2025, 23:22 UTC

Discorsi di Mercato

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12 ott 2025, 23:16 UTC

Acquisizioni, Fusioni, Takeovers

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12 ott 2025, 22:32 UTC

Discorsi di Mercato

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12 ott 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12 ott 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

RPM Global Agrees to Takeover by Caterpillar

12 ott 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11 ott 2025, 08:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

11 ott 2025, 00:18 UTC

Acquisizioni, Fusioni, Takeovers

Why Biotech May Be Back -- Barrons.com

10 ott 2025, 21:07 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10 ott 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

10 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

10 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

10 ott 2025, 20:06 UTC

Discorsi di Mercato

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10 ott 2025, 20:06 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

10 ott 2025, 19:56 UTC

Discorsi di Mercato

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10 ott 2025, 19:20 UTC

Discorsi di Mercato

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10 ott 2025, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10 ott 2025, 18:58 UTC

Discorsi di Mercato

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10 ott 2025, 18:52 UTC

Discorsi di Mercato

PepsiCo Lays Groundwork for Improvement -- Market Talk

10 ott 2025, 18:47 UTC

Discorsi di Mercato

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10 ott 2025, 18:35 UTC

Discorsi di Mercato

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10 ott 2025, 18:31 UTC

Discorsi di Mercato

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10 ott 2025, 17:32 UTC

Discorsi di Mercato

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10 ott 2025, 16:55 UTC

Utili

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10 ott 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

10 ott 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

79.39% in crescita

Previsioni per 12 mesi

Media 80.6 USD  79.39%

Alto 143 USD

Basso 40 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

15

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

158 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat